I ask:
"Why haven't Biophan announced plans to abandon the planned MegaDilution of the float to 800 million shares?"
You reply:
"how about they have, but didn't inform you or any of us?"
In which case I feel bound to point out it wasn't much of an announcement. More like the sound of one hand clapping.
I think existing and potential investors would be re-assured to know that plans to dilute their holdings by 357% have been dropped. Some posters have speculated that they believe these plans have been abandoned.
If they don't confirm it, then people who know Biophan's past record could be forgiven for assuming the worst.
Next: "How are they going to deal with their new senior debtors, led by one (now widely reviled, but unitl recently hero-worshipped) Michael Weiner?"
Your reply:
"are you insinuating toxic financing or just old folks with
money on the line?"
No, I'm remarking that BioMed, led by Michael Weiner need to be watched like hawks. The consensus is that he is incompetent and not to be trusted - even MBD says so. You know the old saying about supping from a long spoon when you dine with the devil.
Next (ignoring the chess remark which didn't make sense, given that I was merely pointing out that letting these guys make an acquisition when they should be focussing on the Myotech CSS development, doesn't seem very sensible, given their past track record):
"Will any new acquisitions result in the syphoning off of tens of millions of dollars from Biophan's balance sheet into private hands..."
Your reply:
"your insinuation of been done before
may be missplaced since the original biomed loan was at a
loss to generate free cash although many saw it as mw lining
his pockets while he was not."
No insinuation of anything. The fact is that Biophan transferred well over ten million dollars to the original private owners of Myovad, or whatever it was called then.
That's money that used to belong to you shareholders.
And now it doesn't, that's clear.
What's not clear is what you shareholders got in return, or why Myotech CSS is always 18-24 months from commercialization. A little like the speed of light, that 18-24 months from market seems to be a universal constant, immutable and immovable.
You request:
"please do not spam the board with other stocks. your
reference has not been discussed on this board at all
to my knowledge. even so it is irrelevant."
Not an unreasonable request, with two minor caveats:
Firstly my reference to Intrepid Technology in no way can be considered spam. I have consistently been negative on that particular stock, and nothing I said could be considered to be an exhortation to buy. Quite the contrary.
More significantly, it is not irrelevant. Quite apart from having the same kind of toxic financing as BIPH had, it has also been promoted by some of the very same posters who promoted Biophan. The recent sad decline is what you might expect from Biophan if it continues its MegaDilution plan, and undergoes the reverse split that would be an inevitable consequence.
Your request not to spam stocks might be better addressed to your new day-trading chums, who leaven their mumbo jumbo about charts and manipulative market makers with numerous references to other stocks with which they attempt to draw (entirely inapposite) parallels with Biophan.
I hope you don't mind me remarking that your tone is a little intemperate. Seems to me you might be a little over-invested here, judging from your obvious hostility.
You might want to chill out a bit.
News 
Market Data 
Discover 
AI
